Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 8,625 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company's stock, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

TransMedics Group Stock Down 2.2 %

TransMedics Group stock traded down $2.82 during mid-day trading on Thursday, reaching $127.15. The stock had a trading volume of 1,010,356 shares, compared to its average volume of 833,459. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The stock's 50-day simple moving average is $154.12 and its 200-day simple moving average is $137.55. The firm has a market capitalization of $4.24 billion, a PE ratio of 3,249.25 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating analysts' consensus estimates of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The firm had revenue of $114.30 million during the quarter, compared to analysts' expectations of $98.84 million. During the same quarter last year, the firm posted ($0.03) earnings per share. The company's revenue for the quarter was up 117.7% compared to the same quarter last year. On average, sell-side analysts forecast that TransMedics Group, Inc. will post 1.22 EPS for the current fiscal year.

Institutional Investors Weigh In On TransMedics Group

Hedge funds have recently added to or reduced their stakes in the company. Fidelis Capital Partners LLC acquired a new stake in TransMedics Group in the first quarter valued at approximately $35,000. International Assets Investment Management LLC bought a new position in shares of TransMedics Group in the second quarter valued at approximately $47,000. USA Financial Formulas bought a new position in shares of TransMedics Group in the third quarter valued at approximately $55,000. J.Safra Asset Management Corp lifted its holdings in shares of TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company's stock valued at $67,000 after purchasing an additional 383 shares in the last quarter. Finally, Signaturefd LLC lifted its holdings in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company's stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on TMDX shares. Morgan Stanley increased their price target on TransMedics Group from $104.00 to $145.00 and gave the company an "equal weight" rating in a research note on Monday, July 15th. Baird R W raised TransMedics Group to a "strong-buy" rating in a research note on Tuesday, September 24th. Oppenheimer increased their price target on TransMedics Group from $125.00 to $200.00 and gave the company an "outperform" rating in a research note on Thursday, August 1st. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 target price on shares of TransMedics Group in a research note on Monday, October 7th. Finally, Canaccord Genuity Group raised their target price on TransMedics Group from $117.00 to $169.00 and gave the stock a "buy" rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $174.30.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.